Physician profile
Anshul Varshney
NPI 1619155991
$1,093.55
in general payments reported to CMS, 2019-2025
13 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.27 · 2020: $23.37 · 2021: $48.75 · 2023: $318 · 2024: $223 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890 · Entertainment: $41.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $889.73 |
| Entertainment | $41.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $492.42 | 2019-2025 | Clareon, Rocklatan |
| Bausch & Lomb Americas INC. | $262.92 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $57.37 | 2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $48.75 | 2021 | |
| Optos, INC. | $41.43 | 2023-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Aerie Pharmaceuticals, INC. | $34.94 | 2019 | |
| Sight Sciences, INC. | $28.38 | 2025 | Omni Surgical System |
| Rxsight INC | $24.20 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Harrow Eye, LLC | $23.47 | 2025 | Vevye |
| Akorn, INC. | $23.37 | 2020 | |
| Horizon Therapeutics Plc | $22.08 | 2023 | Tepezza |
| Shire North American Group INC | $18.06 | 2019 | |
| Thea Pharma INC. | $16.16 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anshul Varshney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.